BCL3 Human shRNA Plasmid Kit (Locus ID 602)

CAT#: TG314491

BCL3 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 602
• Synonyms: BCL4; D19S37
• Vector: pGFP-V-RS
• E. coli Selection: Kanamycin
• Mammalian Cell Selection: Puromycin
• Format: Retroviral plasmids
• Kit Components: BCL3 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 602). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.
• RefSeq: NM_005178, NM_005178.1, NM_005178.2, NM_005178.3, NM_005178.4, BC064993
• UniProt ID: P20749
• Summary: This gene is a proto-oncogene candidate. It is identified by its translocation into the immunoglobulin alpha-locus in some cases of B-cell leukemia. The protein encoded by this gene contains seven ankyrin repeats, which are most closely related to those found in I kappa B proteins. This protein functions as a transcriptional co-activator that activates through its association with NF-kappa B homodimers. The expression of this gene can be induced by NF-kappa B, which forms a part of the autoregulatory loop that controls the nuclear residence of p50 NF-kappa B. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).